Tag: Richard Pazdur
FDA approves AstraZeneca’s Lumoxiti for hairy cell leukaemia treatment
Lumoxiti FDA approval : AstraZeneca has bagged the US Food and Drug Administration (FDA) approval for its CD22-directed cytotoxin Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment ... Read More
FDA approves Agios’ Tibsovo for acute myeloid leukemia treatment
Tibsovo (ivosidenib) developed by Agios Pharmaceuticals has been approved by the US Food and Drug Administration (FDA) for acute myeloid leukemia treatment in patients with ... Read More